The general notion regarding autologous manufacturing is that it has huge challenges, points out Parvathi Chandran, senior manager for research strategy and communication at Regrow Biosciences. “But our experience is that you can work backwards, adapting your manufacturing process, and get a consistent cell therapy product,” she says.
Chandran was speaking to GEN about a recent paper in the BioProcessing Journal. This research outlines Regrow’s study of their autologous cartilage cell therapy that was delivered to 115 patients with cartilage defects in the knee.
